HempTech (HTCO) to build out drug development and manufacturing facility for Biotica Pharmaceuticals—HempTech’s automation technology helps grow pharma grade strains in 2017.
HempTech Corp., a provider of advanced Controlled Environment Agriculture (CEA) with sophisticated automation and analytical tools for the cultivators of legal industrial hemp and marijuana, has agreed to buildout a drug development and manufacturing facility, one of many, for Biotica Pharmaceuticals beginning second quarter 2017.
The new drug development and manufacturing facility will contain grow, lab extraction and laboratory facilities. HempTech will use its most sophisticated grow system, the “grow.droid,” in conjunction with CognetiX for development and delivery of pharmaceutical grade strains for use of medical discovery by Biotica. HempTech is the only cannabis grow technology provider offering advanced CEA and sophisticated analytics for development of pharmaceutical grade marijuana strains for pharmaceuticals globally.
Biotica Pharmaceuticals has developed BPRx technology, which is a novel combinatorial library of phytocannabinoids and endocannabinoids for treating various human diseases. Biotica’s current technology includes;
- BPRx-060216: Lead drug candidate to treat Eosinopilic Esophagitis (EoE)
- BPRx-060234: Lead drug candidate to treat early stages of Alzheimer’s disease
Biotica, a privately held pharmaceutical company, has applied for two world-wide patent rights for the platform technologies and for specific novel drug formulations. They are actively procuring a portfolio of patents, trademarks, and trade secrets to reinforce and protect their technologies. They are conducting discovery research both in-house and with joint development agreements using their platform technology. www.bioticapharma.com.
HempTech supplies technology and automation systems to cannabis growers. www.hemptechcorp.com.
(Source: Marketwired)
Filed Under: Drug Discovery
